Therapy Detail

Therapy Name Tacrolimus
Therapy Description

Tacrolimus binds to FKBP-12 and inhibits calcineurin activity, resulting in immunosuppression (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tacrolimus Hecoria FK-506|Prograf|Advagraf Tacrolimus binds to FKBP-12 and inhibits calcineurin activity, resulting in immunosuppression (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02508038 Phase I Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa Recruiting
NCT01685411 Phase 0 Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam Busulfan and Cyclophosphamide Followed By ALLO BMT Recruiting
NCT00513474 Phase I Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant Completed
NCT02251821 Phase II Fludarabine Tacrolimus Mycophenolate mofetil Busulfan Pacritinib Momelotinib Melphalan Methotrexate Ruxolitinib Cyclophosphamide JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Recruiting
NCT03247088 Phase Ib/II Busulfan + Sorafenib + Fludarabine Cyclophosphamide Tacrolimus Filgrastim Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation Recruiting
NCT01529827 Phase II Melphalan Methotrexate Tacrolimus Mycophenolate mofetil Fludarabine Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting
NCT02081755 Tacrolimus Everolimus Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer Recruiting
NCT01823198 Phase Ib/II Methotrexate Busulfan + Fludarabine + anti-thymocyte globulin Tacrolimus Filgrastim Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies Recruiting
NCT02790515 Phase II Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting
NCT01760655 Phase II Tacrolimus Fludarabine + Thiotepa + Cyclophosphamide Mycophenolate mofetil Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting
NCT01619761 Phase I Rituximab lenalidomide + Fludarabine + Melphalan Mycophenolate mofetil Tacrolimus Natural Killer (NK) Cells in Cord Blood Transplantation Recruiting
NCT02333162 Phase I Mycophenolate mofetil Tacrolimus Fludarabine + Melphalan Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Recruiting
NCT01621477 Phase II Plerixafor Tacrolimus Mycophenolate mofetil Busulfan + Clofarabine + Thymoglobulin Cyclophosphamide + Cytarabine T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated
NCT00857389 Phase II Cyclophosphamide Filgrastim Tacrolimus Thiotepa Busulfan + Clofarabine + Thymoglobulin Methotrexate Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Active, not recruiting
NCT01256398 Phase II Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Vincristine + Methotrexate + Mercaptopurine Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Active, not recruiting
NCT01338987 Phase II Tacrolimus Methotrexate Leuprolide Cyclophosphamide Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation Active, not recruiting
NCT01790568 Phase II Methotrexate Tacrolimus Vorinostat Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant Completed
NCT01701986 Phase Ib/II Tacrolimus Rituximab Filgrastim Mycophenolate mofetil anti-thymocyte globulin Busulfan + Clofarabine + Gemcitabine Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas Recruiting
NCT01203722 Phase Ib/II Tacrolimus Sirolimus Cyclophosphamide + Fludarabine + Mycophenolate mofetil Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Recruiting